Advertisement
Canada markets open in 4 hours 16 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7327
    +0.0003 (+0.05%)
     

  • CRUDE OIL

    83.71
    +0.14 (+0.17%)
     

  • Bitcoin CAD

    87,940.15
    +476.09 (+0.54%)
     

  • CMC Crypto 200

    1,389.38
    -7.15 (-0.51%)
     

  • GOLD FUTURES

    2,360.90
    +18.40 (+0.79%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,725.75
    +158.25 (+0.90%)
     

  • VOLATILITY

    15.60
    +0.23 (+1.50%)
     

  • FTSE

    8,105.19
    +26.33 (+0.33%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6819
    -0.0002 (-0.03%)
     

Has GW Pharmaceuticals (GWPH) Outpaced Other Medical Stocks This Year?

Zacks Equity Research

Investors focused on the Medical space have likely heard of GW Pharmaceuticals (GWPH), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GWPH and the rest of the Medical group's stocks.

GW Pharmaceuticals is one of 844 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. GWPH is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for GWPH's full-year earnings has moved 47.57% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

ADVERTISEMENT

According to our latest data, GWPH has moved about 82.99% on a year-to-date basis. In comparison, Medical companies have returned an average of 5.14%. This shows that GW Pharmaceuticals is outperforming its peers so far this year.

Looking more specifically, GWPH belongs to the Medical - Products industry, a group that includes 77 individual stocks and currently sits at #97 in the Zacks Industry Rank. This group has gained an average of 13.23% so far this year, so GWPH is performing better in this area.

Investors with an interest in Medical stocks should continue to track GWPH. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GW Pharmaceuticals PLC (GWPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research